September 22, 2026.
Ginkgo Bioworks opens “Chromosome Foundry One” in Boston — the world’s first commercial facility dedicated to de novo synthesis of full human chromosomes.
Capacity: 42 complete synthetic chromosomes per month (all 23 pairs possible, custom edits included).
First commercial order: 18 copies of enhanced Chromosome 16 (with added longevity and metabolic genes) for a private longevity consortium.
Price: $42 million per full set.
The same month, Shenzhen’s SynGen Labs ships the first synthetic Chromosome 21 batch to a Singapore clinic.
Thailand’s BioForge announces volume pricing: $18 million per full genome set for orders over 100.
The chromosome factories are online.
Synthetic human DNA is commercial — and the first designer organs are shipping.
The chromosome factory boom – 2026
| Facility / Location | Operator | Monthly capacity (full sets) | Average price per set | Key custom features offered | First commercial shipment |
|---|---|---|---|---|---|
| Ginkgo Foundry One (Boston) | Ginkgo + AltOS | 42 | $42M | Longevity, cognitive boosts | Sep 2026 |
| SynGen Labs (Shenzhen) | Chinese consortium | 120 | $28M | Disease resistance, metabolism | Aug 2026 |
| BioForge (Bangkok) | Thai private | 88 | $18M | Volume discounts, beauty traits | Oct 2026 |
| HelixWorks (Singapore) | State-private | 68 | $32M | Official, regulated | Nov 2026 |
| ChromaSynth (Cyprus) | EU off-shore | 52 | $24M | Privacy-focused | Dec 2026 |
Total global commercial capacity end-2026: 418 full synthetic human genome sets/month
Enough for ~5,000 patients/year at current demand.
The first designer organs – 2026 shipments
- Liver v1.2 (synthetic Chromosome 3 edits): enhanced detoxification, alcohol tolerance +300 %
First recipient: 58-year-old CEO, transplanted Singapore December 2026 - Heart v1.0: synthetic Chromosome 14 with reinforced cardiac genes
First transplant: Dubai, November 2026 - Kidney pair: enhanced filtration, longevity genes
Volume shipments begin Q4 2026
All organs grown in animal surrogates or bioreactors using synthetic chromosome cell lines.
The market explosion – 2026
- Ginkgo valuation: $180 billion
- New entrants: 28 factories announced, $42 billion raised
- “SynHuman Index” ETF: +820 %
- Organ wait-lists: 180,000 names (up from zero 2025)
The regulatory vacuum – 2026
- Singapore: “therapeutic use only” — loosely enforced
- China: state monopoly on distribution, but private factories thrive
- EU/U.S.: “research only” — black/gray market fills gap
- Black market: full chromosome sets $8–$12 million in Thailand back-channels
The first human applications – 2026
- Organ replacement: 820 patients receive synthetic organs
- Embryo edits: 4,200 IVF cycles with synthetic chromosome insertion (full replacement in 180 cases)
- Adult therapy: viral delivery of synthetic chromosome fragments for in-vivo edits (early trials)
The quiet quote from a Ginkgo executive, at Foundry One ribbon-cutting, September 2026
“We’re not editing humans.
We’re writing better versions from scratch.
The old genome was a draft.
This is revision 2.0.
The market wants perfect.
We’re delivering.”
By Christmas 2026, synthetic human chromosomes are shipping.
Designer organs are transplanting.
The revolution is industrial.
Next post: “The Organ Flood – 2027–2028: When Synthetic Hearts Beat in Chests and the Market Offers Full Body Upgrades.”
The code is compiling.
The organs are printing.
The human is upgrading.